Limits...
A multi ‐ biomarker follow ‐ up study of patients with multiple sclerosis

View Article: PubMed Central - PubMed

ABSTRACT

Objectives: This study aimed to examine the levels of the macrophage marker sCD163 and other biomarkers at the time of diagnosis of patients with either clinically isolated syndrome (CIS) or relapsing‐remitting multiple sclerosis (RRMS), and assess relation to clinical indicators of prognosis, disease activity (DA), and changes in the levels of these biomarkers at follow‐up.

Materials and methods: The clinical status and MRI were reevaluated in 56 patients more than 1 year after diagnosis with a median follow‐up time of 2 years. Levels of biomarkers in serum and cerebrospinal fluid (CSF) samples were evaluated by enzyme‐linked immunosorbent assays.

Results: There was no significant difference in time to DA between patients with CIS and RRMS. A high sCD163 ratio (>0.07) was significantly (P = 0.04) associated with time to DA in the untreated patient group. In 21 patients reevaluated with serum and CSF samples, the sCD163 ratio levels decreased from 0.068 to 0.054 (P = 0.026) in the CIS/RRMS‐treated group. The CSF CXCL13, CXCL13 ratio, CSF neurofilament light polypeptide and osteopontin levels also decreased significantly in the CIS/RRMS‐treated group.

Conclusions: The levels of all biomarkers changed concurrently with MS treatment. The sCD163 ratio was identified as a potential novel marker for time to DA.

No MeSH data available.


Related in: MedlinePlus

The untreated and treated patients and their DA rates in relation to levels of the bio marker sCD163. (A–C) are Kaplan–Meier curves illustrating time to DA from diagnosis in UT and TR patients with CIS/RRMS based on CSF sCD163 (A), serum sCD163 (B), and sCD163 ratio (C). Log‐rank test for equality of survivor functions were performed on UT and TR patients with CIS/RRMS, respectively. Abbreviations: UT, untreated; TR, treated; DA, disease activity; CIS, clinically isolated syndrome; RRMS, relapsing‐remitting MS.
© Copyright Policy - creativeCommonsBy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC5036432&req=5

brb3509-fig-0003: The untreated and treated patients and their DA rates in relation to levels of the bio marker sCD163. (A–C) are Kaplan–Meier curves illustrating time to DA from diagnosis in UT and TR patients with CIS/RRMS based on CSF sCD163 (A), serum sCD163 (B), and sCD163 ratio (C). Log‐rank test for equality of survivor functions were performed on UT and TR patients with CIS/RRMS, respectively. Abbreviations: UT, untreated; TR, treated; DA, disease activity; CIS, clinically isolated syndrome; RRMS, relapsing‐remitting MS.

Mentions: The cut points for sCD163 are shown in Figure 3. Here, we also present the Kaplan–Meier plots and the corresponding nonparametric log‐rank tests, which were performed on untreated (UT) and treated (TR) patients with CIS/RRMS, respectively. A high sCD163 ratio was significantly associated to time to DA in the untreated patient group (log‐rank test: P‐value = 0.04) (Fig. 3). Other log‐rank tests on sCD163 were not significant. Similar Kaplan–Meier plots were produced for CXCL13, NfL, NEO, and OPN but log‐rank tests were not significant for any of these biomarkers.


A multi ‐ biomarker follow ‐ up study of patients with multiple sclerosis
The untreated and treated patients and their DA rates in relation to levels of the bio marker sCD163. (A–C) are Kaplan–Meier curves illustrating time to DA from diagnosis in UT and TR patients with CIS/RRMS based on CSF sCD163 (A), serum sCD163 (B), and sCD163 ratio (C). Log‐rank test for equality of survivor functions were performed on UT and TR patients with CIS/RRMS, respectively. Abbreviations: UT, untreated; TR, treated; DA, disease activity; CIS, clinically isolated syndrome; RRMS, relapsing‐remitting MS.
© Copyright Policy - creativeCommonsBy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC5036432&req=5

brb3509-fig-0003: The untreated and treated patients and their DA rates in relation to levels of the bio marker sCD163. (A–C) are Kaplan–Meier curves illustrating time to DA from diagnosis in UT and TR patients with CIS/RRMS based on CSF sCD163 (A), serum sCD163 (B), and sCD163 ratio (C). Log‐rank test for equality of survivor functions were performed on UT and TR patients with CIS/RRMS, respectively. Abbreviations: UT, untreated; TR, treated; DA, disease activity; CIS, clinically isolated syndrome; RRMS, relapsing‐remitting MS.
Mentions: The cut points for sCD163 are shown in Figure 3. Here, we also present the Kaplan–Meier plots and the corresponding nonparametric log‐rank tests, which were performed on untreated (UT) and treated (TR) patients with CIS/RRMS, respectively. A high sCD163 ratio was significantly associated to time to DA in the untreated patient group (log‐rank test: P‐value = 0.04) (Fig. 3). Other log‐rank tests on sCD163 were not significant. Similar Kaplan–Meier plots were produced for CXCL13, NfL, NEO, and OPN but log‐rank tests were not significant for any of these biomarkers.

View Article: PubMed Central - PubMed

ABSTRACT

Objectives: This study aimed to examine the levels of the macrophage marker sCD163 and other biomarkers at the time of diagnosis of patients with either clinically isolated syndrome (CIS) or relapsing‐remitting multiple sclerosis (RRMS), and assess relation to clinical indicators of prognosis, disease activity (DA), and changes in the levels of these biomarkers at follow‐up.

Materials and methods: The clinical status and MRI were reevaluated in 56 patients more than 1 year after diagnosis with a median follow‐up time of 2 years. Levels of biomarkers in serum and cerebrospinal fluid (CSF) samples were evaluated by enzyme‐linked immunosorbent assays.

Results: There was no significant difference in time to DA between patients with CIS and RRMS. A high sCD163 ratio (>0.07) was significantly (P = 0.04) associated with time to DA in the untreated patient group. In 21 patients reevaluated with serum and CSF samples, the sCD163 ratio levels decreased from 0.068 to 0.054 (P = 0.026) in the CIS/RRMS‐treated group. The CSF CXCL13, CXCL13 ratio, CSF neurofilament light polypeptide and osteopontin levels also decreased significantly in the CIS/RRMS‐treated group.

Conclusions: The levels of all biomarkers changed concurrently with MS treatment. The sCD163 ratio was identified as a potential novel marker for time to DA.

No MeSH data available.


Related in: MedlinePlus